213 related articles for article (PubMed ID: 35531606)
1. Targeting Enhancer of Zeste Homolog 2 for the Treatment of Hematological Malignancies and Solid Tumors: Candidate Structure-Activity Relationships Insights and Evolution Prospects.
Xia J; Li J; Tian L; Ren X; Liu C; Liang C
J Med Chem; 2022 May; 65(10):7016-7043. PubMed ID: 35531606
[TBL] [Abstract][Full Text] [Related]
2. Tazemetostat for the treatment of multiple types of hematological malignancies and solid tumors.
Marsh S; Jimeno A
Drugs Today (Barc); 2020 Jun; 56(6):377-387. PubMed ID: 32525136
[TBL] [Abstract][Full Text] [Related]
3. Chromatin remodeling by the histone methyltransferase EZH2 drives lung pre-malignancy and is a target for cancer prevention.
Tellez CS; Picchi MA; Juri D; Do K; Desai DH; Amin SG; Hutt JA; Filipczak PT; Belinsky SA
Clin Epigenetics; 2021 Feb; 13(1):44. PubMed ID: 33632299
[TBL] [Abstract][Full Text] [Related]
4. Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effects.
Huang R; Wu Y; Zou Z
Epigenomics; 2022 Nov; 14(22):1449-1464. PubMed ID: 36601794
[TBL] [Abstract][Full Text] [Related]
5. Covalent inhibitors of EZH2: Design, synthesis and evaluation.
Zhang Q; Chen X; Hu X; Duan X; Wan G; Li L; Feng Q; Zhang Y; Wang N; Yu L
Biomed Pharmacother; 2022 Mar; 147():112617. PubMed ID: 34998031
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in EZH2-based dual inhibitors in the treatment of cancers.
Yang X; Xu L; Yang L
Eur J Med Chem; 2023 Aug; 256():115461. PubMed ID: 37156182
[TBL] [Abstract][Full Text] [Related]
7. Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity.
Bate-Eya LT; Gierman HJ; Ebus ME; Koster J; Caron HN; Versteeg R; Dolman MEM; Molenaar JJ
Eur J Cancer; 2017 Apr; 75():63-72. PubMed ID: 28214660
[TBL] [Abstract][Full Text] [Related]
8. Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas.
Zhou B; Liang X; Mei H; Qi S; Jiang Z; Wang A; Zou F; Liu Q; Liu J; Wang W; Hu C; Chen Y; Wang Z; Wang B; Wang L; Liu J; Liu Q
J Med Chem; 2021 Oct; 64(20):15170-15188. PubMed ID: 34664960
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and evaluation of VHL-based EZH2 degraders for breast cancer.
Xiao B; Shi Z; Liu J; Huang Q; Shu K; Liu F; Zhi C; Zhang D; Wu L; Yang S; Zeng X; Fan T; Liu Z; Jiang Y
Bioorg Chem; 2024 Feb; 143():107078. PubMed ID: 38181661
[TBL] [Abstract][Full Text] [Related]
10. Targeting EZH2 as cancer therapy.
Hanaki S; Shimada M
J Biochem; 2021 Sep; 170(1):1-4. PubMed ID: 33479735
[TBL] [Abstract][Full Text] [Related]
11. Enhancer of zeste homolog 2 (EZH2) inhibitors.
Gulati N; Béguelin W; Giulino-Roth L
Leuk Lymphoma; 2018 Jul; 59(7):1574-1585. PubMed ID: 29473431
[TBL] [Abstract][Full Text] [Related]
12. Six Years (2012-2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2-Pyridone Compounds.
Fioravanti R; Stazi G; Zwergel C; Valente S; Mai A
Chem Rec; 2018 Dec; 18(12):1818-1832. PubMed ID: 30338896
[TBL] [Abstract][Full Text] [Related]
13. Targeting EZH2 for cancer therapy: From current progress to novel strategies.
Zeng J; Zhang J; Sun Y; Wang J; Ren C; Banerjee S; Ouyang L; Wang Y
Eur J Med Chem; 2022 Aug; 238():114419. PubMed ID: 35569264
[TBL] [Abstract][Full Text] [Related]
14. Drugging histone methyltransferases in cancer.
Richart L; Margueron R
Curr Opin Chem Biol; 2020 Jun; 56():51-62. PubMed ID: 31981999
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
[TBL] [Abstract][Full Text] [Related]
16. [Research Progress of Expression and Clinical Significant of EZH2 in Hematological Malignancies--Review].
Hu JY; Ji YR; Liu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):2097-2012. PubMed ID: 33283749
[TBL] [Abstract][Full Text] [Related]
17. Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.
Honma D; Kanno O; Watanabe J; Kinoshita J; Hirasawa M; Nosaka E; Shiroishi M; Takizawa T; Yasumatsu I; Horiuchi T; Nakao A; Suzuki K; Yamasaki T; Nakajima K; Hayakawa M; Yamazaki T; Yadav AS; Adachi N
Cancer Sci; 2017 Oct; 108(10):2069-2078. PubMed ID: 28741798
[TBL] [Abstract][Full Text] [Related]
18. Design, Synthesis, and Biological Evaluation of a Potent Dual EZH2-BRD4 Inhibitor for the Treatment of Some Solid Tumors.
Huang N; Liao P; Zuo Y; Zhang L; Jiang R
J Med Chem; 2023 Feb; 66(4):2646-2662. PubMed ID: 36774555
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and evaluation of EZH2-based PROTACs targeting PRC2 complex in lymphoma.
Xie H; Xu W; Liang J; Liu Y; Zhuo C; Zou X; Luo W; Xiao J; Lin Y; Chen L; Li H
Bioorg Chem; 2023 Nov; 140():106762. PubMed ID: 37572533
[TBL] [Abstract][Full Text] [Related]
20. Symphony of epigenetic and metabolic regulation-interaction between the histone methyltransferase EZH2 and metabolism of tumor.
Zhang T; Gong Y; Meng H; Li C; Xue L
Clin Epigenetics; 2020 May; 12(1):72. PubMed ID: 32448308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
